COR logo

CENCORA INC

CORNYSE
πŸ† #215 by market capEarnings Nov 3 Β· PostUS Equity
$333.91β–² $9.25 (+2.77%)
Live
1hβ€”
24hβ–² 2.8%
7dβ–² 5.3%
14dβ–² 4.8%
30dβ–² 9.1%
1yβ–² 15.4%
🏦Market Cap
$64.96B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
+5.1%
Slowing
πŸ“ŠGross Margin
4.0%
Thin
πŸ’΅FCF Margin
1.9%
Thin
βš–οΈP/S Ratio
0.2x
Cheap
Otter Score
42
Weak

Trading Snapshot

Day Range
$330.52 – $340.42
52-Week Range
$244.82 – $377.54
Volume
$3.20B
Avg Volume
$3.93B
Shares Outstanding
194.6M
Next Earnings
Sep 14, 2026

Fundamentals Snapshot

Annual Revenue
$332.72B
Last Q Revenue
$74.94B
P/E Ratio
23.6
P/S Ratio
0.2x
EPS (TTM)
$13.45
Dividend Yield
0.75%

Why Investors Own COR

  • βœ“High-growth profile β€” revenue up +16.6% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 26% gross margin and 15% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$332.72Bβ–² +15.5% YoY
Gross Margin (TTM)
26.2%β–² +3.3% YoY
Operating Income (TTM)
$73.86Bβ–² +15.5% YoY
Free Cash Flow (TTM)
$50.24Bβ–² +15.5% YoY

About CENCORA INC

A company profile for CENCORA INC isn’t available yet β€” check back soon.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
42/100

Analyst Ratings

β“˜
Consensus
Buy
20 analysts
Strong Buy5
Buy10
Hold5
Sell0
Strong Sell0
Ratings as of Aug 2026

Latest News & Updates

πŸš€
BenzingaΒ·15h ago

Wells Fargo Maintains Overweight on Cencora, Raises Price Target to $395

Wells Fargo analyst Stephen Baxter maintains Cencora (NYSE:COR) with a Overweight and raises the price target from $331 to $395.

YahooΒ·4d ago

AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie generates stronger free cash flow and trades at a lower forward multiple, while Abbott offers diversification and a healthier balance sheet.

YahooΒ·4d ago

Will Pharma and Specialty Demand Boost Cardinal Health's Q4 Results?

Cardinal Health heads into Q4 earnings with pharma, specialty and higher-margin businesses in focus as investors watch if growth offsets pricing headwinds.

SeekingAlphaΒ·4d ago

Dividend Champion, Contender, And Challenger Highlights: Week Of August 9

Weekly dividend activity roundup for Dividend Champions, Contenders & ChallengersҀ”see dividend changes, upcoming ex-dividend dates and pay dates here.

πŸ›°οΈ
BenzingaΒ·4d ago

Morgan Stanley Maintains Overweight on Cencora, Raises Price Target to $346

Morgan Stanley analyst Erin Wright maintains Cencora (NYSE:COR) with a Overweight and raises the price target from $342 to $346.

🌌
BenzingaΒ·4d ago

JP Morgan Maintains Overweight on Cencora, Raises Price Target to $390

JP Morgan analyst Lisa Gill maintains Cencora (NYSE:COR) with a Overweight and raises the price target from $382 to $390.